ESMOLOL HCL/ORPHA 2500MG/10ML C/S.SOL.IN Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

esmolol hcl/orpha 2500mg/10ml c/s.sol.in

orpha-devel handels und vertriebs gmbh, austria - esmolol - ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ - 2500mg/10ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

MEMANTIN/TORRENT 10MG/ML (5MG/PUMP) ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

memantin/torrent 10mg/ml (5mg/pump) ποσιμο διαλυμα

torrent pharma gmbh, nuremberg, germany (0000007065) suedwestpark 50,, 90449 nuremberg - memantine hydrochloride - ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ - 10mg/ml (5mg/pump) - 8000041261 memantine hydrochloride 10.000000 mg - memantine

Comirnaty Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Εμβόλια - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

TRIENTINE/TILLOMED CAPS 167MG/CAP Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

trientine/tillomed caps 167mg/cap

tillomed pharma gmbh, schonefeld, germany mittelstrabe 5/5a , 12529 schonefeld - trientine dihydrochloride - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 167mg/cap - trientine dihydrochloride 250mg - trientine

Aquipta Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

aquipta

abbvie deutschland gmbh & co. kg - atogepant - Διαταραχές της ημικρανίας - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Phesgo Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

phesgo

roche registration gmbh - pertuzumab, trastuzumab - Νεοπλάσματα του μαστού - Αντινεοπλασματικοί παράγοντες - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.